Full Press Release Details
Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients
PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year’s summit is From Hope to Product – The Brilliant Prospect in Nanomedicine and Related Fields.
Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, ‘From Bench to Bedside: D-PLEX100 Limits AMR Occurrence in Randomized Double-Blind Phase 2 Trial in Colorectal Surgery Patients,’ demonstrating D-PLEX100 as a safe and effective surgical site infection prevention agent without affecting the incidence of postoperative colonization by multi drug resistant organisms. Dr. Emanuel’s presentation will be available on https://www.polypid.com/ following the summit.
Dikla Czaczkes Akselbrad